We have been deeply engaged in the structural analysis of Recombinant Humanized Collagen, with 11 atomic-resolution collagen structures successfully submitted to and archived by the Protein Data Bank (PDB)—the world’s most authoritative database for protein structures. Notably, our type V and type XVIⅠ collagen models remain the only entries of their kind currently available in the PDB, underscoring our globally leading position in the study of these collagen subtypes. With robust in-house capabilities in structural elucidation, we are now one of the world’s most prolific contributors of humanized collagen structural data.

The paper"Characterization by high-resolution crystal structure analysis of a triple-helix region of human collagen type III with potent cell adhesion activity", co-authored by core members of our research team, was the first to resolve the high-resolution triple-helical structure of a functional domain of human type III collagen. This seminal study confirmed its exceptional cell adhesion properties, laying a solid theoretical foundation for the development of next-generation Recombinant Humanized Collagen-based biomaterials.

Building on this foundational research, our work not only supports the rational design and development of high-performance collagen biomaterials, but also showcases our capability to translate foundational research into applicable technologies and consumer products. We remain committed to advancing the understanding of collagen structure–function relationships, accelerating the transformation of scientific breakthroughs into everyday personal care solutions.

The U.S. invention patent (US 11,396,537 B) recoginizes our collagen for the structural design and expression methods of key functional fragments of recombinant collagen, highlighting functional collagen moleculesdevelopment.

Our cutting-edge research and development in recombinant collagen materials has provided critical technical support for the issuance of the National Medical Products Administration’s (NMPA) “YY/T 1888-2023 Guidelines for Nomenclature of Recombinant Collagen Biomaterials”.

As the first registered entity (Document No. 001) to complete the filing for recombinant collagen, we have pioneered the compliance process in this field. As the principal drafter of the first national nomenclature standard and the foremost compliant registrant in this sector, we have effectively driven the formal classification and regulatory institutionalization of recombinant collagen within China’s oversight system.

Our recombinant human type III collagen features a flexible triple-helix structure with a 164.88° angle, exhibiting superior cell adhesion compared to natural collagen. It forms ECM-like fibrous networks, offering excellent tissue support and repair functions. This collagen is expected to have broad preclinical applications in vascular, uterine, oral, and orthopedic fields.

From heart surgery to aesthetic injections -- and now, into daily skincare -- our Recombinant Humanized Collagen brings medical-grade biotechnology into everyday use. This ingredient, or rather, the clinical-backed and biocompatible super material, delivers visible anti-aging results with precision, safety, and care.